Lucid Diagnostics Inc Asset Resilience Ratio
Lucid Diagnostics Inc asset resilience ratio. Lucid Diagnostics Inc (LUCD) has an Asset Resilience Ratio of 6.09% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LUCD defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lucid Diagnostics Inc (2019–2022)
Asset resilience ratio of Lucid Diagnostics Inc from 2019 to 2022. This chart shows how Lucid Diagnostics Inc's Asset Resilience Ratio has changed over time. Read LUCD total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lucid Diagnostics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LUCD current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.59 Million | 6.09% |
| Total Liquid Assets | $2.59 Million | 6.09% |
Asset Resilience Insights
- Limited Liquidity: Lucid Diagnostics Inc maintains only 6.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lucid Diagnostics Inc Industry Peers by Asset Resilience Ratio
Compare Lucid Diagnostics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Lucid Diagnostics Inc Asset Resilience Ratio by Year (2019–2022)
Lucid Diagnostics Inc asset resilience ratio by year from 2019 to 2022. The table below shows the annual Asset Resilience Ratio data for Lucid Diagnostics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 4.09% | $1.33 Million | $32.51 Million | +2.20pp |
| 2021-12-31 | 1.89% | $1.12 Million | $59.00 Million | -3.48pp |
| 2020-12-31 | 5.38% | $118.00K | $2.19 Million | -6.05pp |
| 2019-12-31 | 11.42% | $118.09K | $1.03 Million | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with th… Read more